NCT03381547View on ClinicalTrials.gov

A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

February 11, 2018

Study Completion Date

February 11, 2018

Conditions

Healthy Adult Subjects

Interventions

BIOLOGICAL

Pegilodecakin

Pegilodecakin Alone

Trial Locations (1)

78744

PPD Development, Austin

Sponsors

Collaborators (1)

ARMO BioSciences

All Listed Sponsors

collaborator

ARMO BioSciences

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY